3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Advanced Cancer
4
Stomach Neoplasms
1
Solid Tumor
1
Pancreatic Neoplasms
1
Neoplasms
1
Gallbladder Neoplasms
1
Cholangiocarcinoma
1
Biliary Tract Neoplasms
1
Bile Duct Neoplasms
1
Interventions
Gemcitabine
60
Cisplatin
38
Oxaliplatin
30
Capecitabine
28
Fluorouracil
21
Leucovorin
19
pembrolizumab
11
Irinotecan
11
durvalumab
9
130-nm albumin-bound paclitaxel
9
Erlotinib Hydrochloride
8
Trastuzumab
7
Bevacizumab
7
Platinum
6
Magnetic Resonance Spectroscopy
6
Albumin-Bound Paclitaxel
6
1,2-diaminocyclohexaneplatinum II citrate
6
Taxes
5
Specimen Handling
5
Sorafenib
5
Radiotherapy
5
Carboplatin
5
Docetaxel
4
Biopsy
4
trifluridine tipiracil drug combination
3
dehydroftorafur
3
atezolizumab
3
Paclitaxel
3
Lapatinib
3
Interleukin-12 Subunit p35
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Gallbladder Neoplasms
×
ARRY-334543
×
Clear all
NCT03093870
2021-08-03
TreeTopp
ASLAN Pharmaceuticals
Phase 2/3
Completed
151 enrolled
18 charts